How did Halotier's revenue and expenses trend in Q1 2025?

Halozyme Therapeutics (HALO) experienced a total revenue of $264.86 million in Q1 2025, with R&D expenses amounting to $14.8 million and selling, general, and administrative expenses totaling $60.12 million.

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|Total Revenue|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|---|---|
|HALO|HALO.O|Halozyme Therapeutics|2024 Q2|5.3473E7|2.1038E7|2.31353E8||185|
|HALO|HALO.O|Halozyme Therapeutics|2024 Q3|5.9003E7|1.8458E7|2.90084E8||185|
|HALO|HALO.O|Halozyme Therapeutics|2024 Q4|6.0011E7|2.0441E7|2.98008E8||185|
|HALO|HALO.O|Halozyme Therapeutics|2025 Q1|6.0124E7|1.4799E7|2.64861E8||185|